Heron Therapeutics, Inc.

Contributing Author

Recent Articles by Heron Therapeutics, Inc.

Jan-09	Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF Largest Contributor to Q4 Growth HRTX +9.45% GlobeNewswire
Dec-04	Heron Therapeutics Announces Inclusion of APONVIE (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) HRTX GlobeNewswire
Nov-04	Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress HRTX GlobeNewswire
Oct-29	Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors HRTX GlobeNewswire
Oct-21	Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 HRTX -8.46% HRTX GlobeNewswire